Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2025-11-20
DOI
https://doi.org/10.1002/jha2.70182
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma

Raza Ur Rehman
eJHaem
CAR-T cell therapy research
article

Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma

Raza Ur Rehman
article en

Abstract

No abstract available for this paper.
eJHaemVol. 6(6)
Shaikh Zayed Postgraduate Medical Institute (PK)
Openalex Percentile: Top 52%
CAR-T cell therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lynozyfic (Linvoseltamab): A First‐in‐Class Off‐the‐Shelf T‐Cell Redirector for Refractory Multiple Myeloma — Raza Ur Rehman · eJHaem (2025) | TGRS Research Map | TGRS